Targeting– tag –
-
Wugen Rebrands as Allotera, Closes $35 Million Financing Round to Accelerate Off-the-Shelf Cell Therapy Development for Cancer and Autoimmune Diseases
Cellgenetherapyreview.com USA Overview On July 10, 2026, Wugen announced its rebranding to Allotera and the successful completion of a $35 million financing round. This rebranding and capital infusion represent a significant strategic st... -
Lyora Launches with Seed Funding to Propel Ophthalmic Gene Therapy Assets, Targeting IND Submission Within 18 Months
Cellgenetherapyreview.com USA Overview Lyora announced on July 14, 2026, the successful completion of its seed funding round and the official launch of operations, aimed at advancing its ophthalmic gene therapy assets. The company plans ... -
Tempest Therapeutics to Advance In Vivo CAR T-Cell Therapy TPST-4003 into Clinical Trials by Year-End for Autoimmune Diseases like Myasthenia Gravis and Multiple Sclerosis
Biotech News Portal USA Overview Tempest Therapeutics announced on July 16, 2026, that its lead in vivo CAR T-cell product candidate, TPST-4003, is slated to enter clinical trials by year-end. This candidate will be evaluated in investig... -
Beyond RNA: DNA-Guided CRISPR Heralds a New Era of Precision Gene Editing
Liv Hospital Turkey Overview Liv Hospital reports a significant shift in CRISPR gene editing, moving from conventional RNA-guided to potentially more stable and precise DNA-guided systems. This evolution, coupled with advancements in del... -
Fate Therapeutics Secures FDA IND Clearance for FT839, a Dual iPSC-Derived CAR T-Cell Candidate, with Phase 1/2a Trial Targeting Autoimmune Diseases and Hematologic Malignancies to Commence in H2 2026
GlobeNewswire USA Overview Fate Therapeutics announced FDA IND clearance for FT839, its iPSC-derived dual CAR T-cell product candidate. FT839 is designed to simultaneously target CD19 and CD38, aiming for comprehensive treatment across a... -
Fate Therapeutics’ Off-the-Shelf iPSC-Derived CAR T-Cell Therapy FT819 Shows Promising Early Clinical Data in Treatment-Resistant Systemic Sclerosis
EurekAlert! USA Overview New preliminary clinical data for Fate Therapeutics' off-the-shelf iPSC-derived CAR T-cell therapy, FT819, was presented at ISSCR 2026, targeting patients with treatment-resistant systemic sclerosis. As part of a... -
Taiwan’s ITRI Establishes Highly Stable iPSC-Based MSC and Exosome Manufacturing Platform to Advance Regenerative Medicine
Industrial Technology Research Institute (ITRI) Taiwan Overview Taiwan's Industrial Technology Research Institute (ITRI) has established a highly stable iPSC-based mesenchymal stem cell (MSC) and exosome manufacturing platform. This plat... -
Imunopharm Files for Shanghai STAR Market IPO, Targeting $550 Million Valuation to Expand CAR-T and CDMO Business
VCBeat China Overview Chinese biotechnology firm Imunopharm has filed for an Initial Public Offering (IPO) on the Shanghai STAR Market, targeting a valuation of 4 billion RMB (approximately $550 million). The company's pipeline includes ... -
Fate Therapeutics Receives FDA IND Approval for CAR-T Therapy FT839 for Autoimmune Diseases, Advancing to Phase 1/2 Clinical Trial
GlobeNewswire USA Overview Fate Therapeutics has received U.S. FDA Investigational New Drug (IND) approval for its CAR-T cell therapy candidate, FT839, targeting autoimmune diseases. The company plans to initiate a Phase 1/2 basket clini... -
iPSC-Derived Off-the-Shelf CAR T Therapy FT819 Shows Promising Safety and Efficacy Signals for Treatment-Resistant Systemic Sclerosis at ISSCR 2026
News-Medical.Net - An AZoNetwork Site USA Overview Preliminary clinical data for FT819, an iPSC-derived CAR T-cell therapy targeting treatment-resistant systemic sclerosis, were presented at the ISSCR 2026 Annual Meeting. FT819 is manufa...
